# Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PD

> **NIH NIH P30** · STANFORD UNIVERSITY · 2022 · $345,162

## Abstract

PROJECT SUMMARY
The Stanford Alzheimer's Disease Research Center supports the National Alzheimer's Project Act by serving
as a shared resource to promote research on Alzheimer's disease, cognitive impairment linked to Lewy body
changes in the brain, and cognitive aging.
Clearly, within the scope of the parent Stanford ADRC, this Administrative Supplement respectfully requests
supplemental funding for the Stanford ADRC Neuropathology Core to take responsibility for the derivation,
characterization, and banking of 20 new human induced pluripotent stem cell (iPSC) lines and to assess
biomarkers in iPSC-derived neuronal and microglia cultures for AD and PD. In particular, we support and
expand Aim 4 of the parent ADRC to “make available participant biospecimens and high-content biospecimen
data” by generating new iPSC lines that can be differentiated into neuronal and glia cultures and recapitulate
many molecular and phenotypic aspects of AD and PD.
The Aims of this study are: (1) the derivation of 60 new human iPSC clones from 20 existing ADRC
human skin fibroblasts lines with defined clinical phenotypes and genetic characterization within the AD
spectrum (AD-dementia, AD-mild cognitive impairment) and Lewy body spectrum (Parkinson’s disease,
dementia with Lewy bodies), matched with healthy controls. We use non-integrating reprogramming methods
to develop these iPSC clones. All clones will undergo rigorous quality control testing in accordance with NIH
guidelines. (2) AD/ADRD phenotypic characterization of iPSC neurons and microglia. We will differentiate
cell lines into cortical neurons and microglia using established protocols, develop multiplex imaging
phenotyping and expression panels for AD and PD-related neuropathology (Aim 2.1), and test lysates and
media supernatant for established AD biomarkers, including tau, hyperphosphorylated tau, A1-40, and A1-42,
alpha-synuclein aggregates and compare analyses to cerebrospinal fluid biomarkers in corresponding samples
from the same donor (Aim 2.2). (3) Banking and distribution of iPSC lines to the NCRAD biobank (Aim 3a).
We will collaborate across centers to innovate the development of new resources, such as directly transformed
neurons and human organoids (in collaboration with UC San Diego’s iPSC Core) and the development of
microglia and chimera models (in collaboration with UC Irvine’s iPSC Core) (Aim 3b).
When successfully completed, the work proposed in this supplement will yield 60 new iPSC clones from 20
clinically and genetically well-characterized ADRC participants, and we will share all lines with the NCRAD
repository, the research community at Stanford and beyond. This resource will expand the Stanford ADRC
tissue resource repertoire and allow the scientific community to work with advanced predictive human cellular
model systems.

## Key facts

- **NIH application ID:** 10653524
- **Project number:** 3P30AG066515-03S1
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Victor Henderson
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $345,162
- **Award type:** 3
- **Project period:** 2020-06-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10653524

## Citation

> US National Institutes of Health, RePORTER application 10653524, Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PD (3P30AG066515-03S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10653524. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*